biomarker_id biomarker assessed_biomarker_entity assessed_biomarker_entity_id assessed_entity_type condition condition_id exposure_agent exposure_agent_id best_biomarker_role specimen specimen_id loinc_code evidence_source evidence tag vocab_pattern biomarker_controlled_vocab component_group flags BMKB151634-1 buta-1,3-diene buta-1,3-diene CHEBI:39478 metabolite cancer DOID:162 NCIt:C29790 A synthetic, colorless gas that is practically insoluble in water and soluble in ethanol, ether, acetone and benzene. It is used primarily as a monomer to manufacture many different types of polymers and copolymers and as a chemical intermediate in the production of industrial chemicals. When heated, 1,3-butadiene emits acrid fumes and is flammable. In the presence of air, it oxidizes to form explosive peroxides. The primary route of potential human exposure to this compound is inhalation. Acute exposure to 1,3-butadiene can cause irritation of the eyes, nasal passages and throat. At very high concentrations, inhalation of this gas can result in headache, fatigue, decreased blood pressure and pulse rate, central nervous system damage and unconsciousness. It is known to be a human carcinogen. (NCI05) buta-1,3-diene [biomarker_term_in_review] 1 not_mapped BMKB151629-1 1-methylhistidine 1-methylhistidine CHEBI:70958 metabolite cancer DOID:162 urine UBERON:0001088 27044-7 NCIt:C118886 A histidine derivative that has a methyl group bound to the nitrogen at position 1 and results from the metabolism of the dipeptide anserine. Urinary levels of 1-methylhistidine may be indicative of myofibrillar protein degradation or a high protein diet. 1-methylhistidine [biomarker_term_in_review] 2 not_mapped BMKB151629-1 1-methylhistidine 1-methylhistidine CHEBI:70958 metabolite cancer DOID:162 urine UBERON:0001088 25318-7 NCIt:C118886 A histidine derivative that has a methyl group bound to the nitrogen at position 1 and results from the metabolism of the dipeptide anserine. Urinary levels of 1-methylhistidine may be indicative of myofibrillar protein degradation or a high protein diet. 1-methylhistidine [biomarker_term_in_review] 2 not_mapped BMKB151615-1 11-dehydro-thromboxane B2 11-dehydro-thromboxane B2 CHEBI:28667 metabolite cancer DOID:162 urine UBERON:0001088 49734-7 NCIt:C103344 The determination of the amount of the 11-dehydro-thromboxane B2 in a sample. 11-dehydro-thromboxane B2 [biomarker_term_in_review] 3 not_mapped BMKB151619-1 11-deoxycortisol 11-deoxycortisol CHEBI:28324 metabolite cancer DOID:162 40810-4 NCIt:C80813 A glucocorticoid that is an intermediate in the biosynthesis of cortisol in the adrenal gland. 11-deoxycortisol [biomarker_term_in_review] 4 not_mapped BMKB151630-1 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol CHEBI:77273 metabolite tetrahydrocannabinol PCCID:16078 urine UBERON:0001088 102041-1 NCIt:C221813 An inactive, long-lasting metabolite of tetrahydrocannabinol (THC), which is the psychoactive component of cannabis. After consumption of cannabis, THC is metabolized to the active metabolite 11-hydroxy-THC (11-OH-THC) by liver enzymes and converted to 11-Nor-9-carboxy-delta(9)-tetrahydrocannabinol (11-COOH-THC) through oxidation in the liver. 11-COOH-THC can be used as a biomarker for THC exposure and 11-COOH-THC can be found in urine, blood, and hair. 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol [biomarker_term_in_review] 5 not_mapped BMKB151630-1 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol CHEBI:77273 metabolite tetrahydrocannabinol PCCID:16078 blood UBERON:0000178 42492-9 NCIt:C221813 An inactive, long-lasting metabolite of tetrahydrocannabinol (THC), which is the psychoactive component of cannabis. After consumption of cannabis, THC is metabolized to the active metabolite 11-hydroxy-THC (11-OH-THC) by liver enzymes and converted to 11-Nor-9-carboxy-delta(9)-tetrahydrocannabinol (11-COOH-THC) through oxidation in the liver. 11-COOH-THC can be used as a biomarker for THC exposure and 11-COOH-THC can be found in urine, blood, and hair. 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol [biomarker_term_in_review] 5 not_mapped BMKB151630-1 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol CHEBI:77273 metabolite tetrahydrocannabinol PCCID:16078 hair UBERON:0001037 LP14468-0 NCIt:C221813 An inactive, long-lasting metabolite of tetrahydrocannabinol (THC), which is the psychoactive component of cannabis. After consumption of cannabis, THC is metabolized to the active metabolite 11-hydroxy-THC (11-OH-THC) by liver enzymes and converted to 11-Nor-9-carboxy-delta(9)-tetrahydrocannabinol (11-COOH-THC) through oxidation in the liver. 11-COOH-THC can be used as a biomarker for THC exposure and 11-COOH-THC can be found in urine, blood, and hair. 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol [biomarker_term_in_review] 5 not_mapped BMKB151616-1 11p15 loss of heterozygosity 11p15 loss of heterozygosity NCIt:C219070 gene cancer DOID:162 NCIt:C219070 A molecular abnormality characterized by monoallelic loss of function mutations within the p15 band on the short arm of chromosome 11. 11p15 loss of heterozygosity [biomarker_term_in_review] 6 not_mapped BMKB151628-1 11q deletion loss of chromosome 11q NCIt:C37312 gene cancer DOID:162 NCIt:C37312 A cytogenetic abnormality that refers to the allelic loss of all or part of the long arm of chromosome 11. change_type:presence of;mod_type:sequence variation Presence of bmkb_II::11q:deletion sequence variation in gene loss of chromosome 11q/NCBI: 7 BMKB151613-1 11q translocation 11q translocation NCIt:C133693 gene cancer DOID:162 NCIt:C133693 A cytogenetic abnormality that refers to any translocation involving the long arm of chromosome 11. 11q translocation [biomarker_term_in_review] 8 not_mapped BMKB151623-1 11q22-23 deletion del(11q22q23) NCIt:C36422 gene cancer DOID:162 NCIt:C36422 A chromosomal aberration where there is a loss of part of the long arm of chromosome 11, which deletes the chromosomal bands q22 and q23. change_type:presence of;mod_type:sequence variation Presence of bmkb_II::11q22-23:deletion sequence variation in gene del(11q22q23)/NCBI: 9 BMKB151622-1 11q23 abnormality 11q23 abnormality NCIt:C158685 gene cancer DOID:162 NCIt:C158685 Any cytogenetic abnormality involving chromosome band 11q23. 11q23 abnormality [biomarker_term_in_review] 10 not_mapped BMKB151621-1 11q23 translocation translocation 11q23 NCIt:C36517 gene cancer DOID:162 NCIt:C36517 A chromosomal abnormality consisting of the translocation of genetic material from any one of several chromosomes to the 11q23.3 region, resulting in an MLL gene rearrangement. 11q23 translocation [biomarker_term_in_review] 11 not_mapped BMKB151633-1 12-HETE 12-HETE CHEBI:19138 metabolite cancer DOID:162 NCIt:C959 A metabolite generated from arachidonic acid by 12S-type arachidonate 12-lipoxygenase in platelets. 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12(S)-HETE) may be involved in inflammation and pruritus. 12-HETE [biomarker_term_in_review] 12 not_mapped BMKB151617-1 12-methyltetradecanoic acid 12-methyltetradecanoic acid CHEBI:39251 lipid cancer DOID:162 NCIt:C105827 A branched-chain saturated fatty acid that is comprised of tetradecanoic acid with a methyl group on the carbon in the twelfth position. 12-methyltetradecanoic acid [biomarker_term_in_review] 13 not_mapped BMKB151625-1 12p deletion loss of chromosome 12p NCIt:C36410 gene cancer DOID:162 NCIt:C36410 A cytogenetic abnormality that refers to the allelic loss of all or part of the short arm of chromosome 12. change_type:presence of;mod_type:sequence variation Presence of bmkb_II::12p:deletion sequence variation in gene loss of chromosome 12p/NCBI: 14 BMKB151612-1 13-HODE 13-HODE CHEBI:72639 lipid cancer DOID:162 NCIt:C131741 A monohydroxy fatty acid resulting from the oxidation of linoleic acid or 13-hydroperoxy-9,11-octadecadienoic acid (13-HpODE). 13-HODE may mediate physiological and pathological responses and is a potential biomarker of various human diseases, and could contribute to the progression of certain diseases. 13-HODE [biomarker_term_in_review] 15 not_mapped BMKB151631-1 (12)(13)-methyltetradecanoic acid (12)(13)-methyltetradecanoic acid CHEBI:232769 lipid cancer DOID:162 NCIt:C105828 A branched-chain saturated fatty acid that is comprised of tetradecanoic acid with a methyl group on the carbon in the thirteenth position. (12)(13)-methyltetradecanoic acid [biomarker_term_in_review] 16 not_mapped BMKB151618-1 13q deletion loss of chromosome 13q NCIt:C36497 gene cancer DOID:162 NCIt:C36497 A cytogenetic abnormality that refers to the allelic loss of all or part of the long arm of chromosome 13. change_type:presence of;mod_type:sequence variation Presence of bmkb_II::13q:deletion sequence variation in gene loss of chromosome 13q/NCBI: 17 BMKB151611-1 16alpha-hydroxyestrone 16alpha-hydroxyestrone CHEBI:776 metabolite cancer DOID:162 49825-3 NCIt:C120468 A metabolite formed during the catabolism of estrone by the liver through the hydroxylation of the carbon at position 16 by cytochrome P450 (CYP) family enzymes, including CYP3A4 and 3A5, with potential carcinogenic activity. With increased estrogenic activity compared to the parent compound, 16alpha-hydroxyestrone (16alpha-OHE1) increases the expression of ER-responsive genes, which leads to increased proliferation of susceptible tumor cells. The ratio between the two estrogen metabolites, 2-hydroxyestrone (2-OHE1), a weak estrogen and metabolite from the 2-hydroxylation pathway, and 16alpha-OHE1, a metabolite from the 16-hydroxylation pathway, may be used to assess the risk of certain cancers; a higher ratio of 2-OHE1:16alpha-OHE1 correlates with decreased cancer risk. 16alpha-hydroxyestrone [biomarker_term_in_review] 18 not_mapped BMKB151627-1 16-Hydroxyestrogens 16-Hydroxyestrogen NCIt:C113817 metabolite cancer DOID:162 NCIt:C113817 Any metabolite formed during the catabolism of estrogens by the liver through the hydroxylation of the carbon at position 16 by the enzymes, cytochrome P450 3A4 and 1B1. The 16-hydroxyestrogens may have high estrogenic activity and preferential formation of 16-hydroxyestrogen metabolites may be associated with an elevated risk for breast cancer. 16-Hydroxyestrogens [biomarker_term_in_review] 19 not_mapped BMKB151624-1 17alpha-hydroxyprogesterone 17alpha-hydroxyprogesterone CHEBI:17252 metabolite cancer DOID:162 blood serum UBERON:0001977 1668-3 NCIt:C87242 A physiological progestin that is produced during glucocorticoid and steroid hormone synthesis and is increased during the third trimester of pregnancy. Hydroxyprogesterone binds to the cytoplasmic progesterone receptors in the reproductive system and subsequently activates progesterone receptor mediated gene expression. 17alpha-hydroxyprogesterone [biomarker_term_in_review] 20 not_mapped BMKB151624-1 17alpha-hydroxypregnenolone 17alpha-hydroxypregnenolone CHEBI:28750 metabolite cancer DOID:162 LP17184-0 NCIt:C107138 An endogenous steroid hormone synthesized by the hydroxylation of pregnenolone, which can act either as a neuroactive steroid or as a prohormone for progestogens, mineralocorticoids, glucocorticoids, androgens, estrogens, and the neuroactive steroids. 17alpha-hydroxypregnenolone [biomarker_term_in_review] 20 not_mapped BMKB151614-1 17p deletion loss of chromosome 17p NCIt:C36499 gene cancer DOID:162 NCIt:C36499 A cytogenetic abnormality that refers to the allelic loss of all or part of the short arm of chromosome 17. change_type:presence of;mod_type:sequence variation Presence of bmkb_II::17p:deletion sequence variation in gene loss of chromosome 17p/NCBI: 21 BMKB151610-1 17p13 deletion del(17p13) NCIt:C36424 gene cancer DOID:162 NCIt:C36424 A deletion of chromosomal material at 17p13. This chromosomal aberration includes deletion of the TP53 gene and is associated with multiple myeloma, chronic lymphocytic leukemia, acute myeloid leukemia and myelodysplastic syndrome. change_type:presence of;mod_type:sequence variation Presence of bmkb_II::17p13:deletion sequence variation in gene del(17p13)/NCBI: 22 BMKB151626-1 17p13.1 deletion del(17p13.1) NCIt:C165729 gene cancer DOID:162 NCIt:C165729 A deletion of chromosomal material at 17p13.1. This chromosomal aberration includes deletion of the TP53 gene and is associated with chronic lymphocytic leukemia. change_type:presence of;mod_type:sequence variation Presence of bmkb_II::17p13.1:deletion sequence variation in gene del(17p13.1)/NCBI: 23 BMKB151632-1 1D10 Antigen 1D10 Antigen NCIt:C126900 protein cancer DOID:162 NCIt:C126900 A polymorphic epitope on the HLA-DR beta chain that is expressed on normal and neoplastic B-cells. 1D10 Antigen [biomarker_term_in_review] 24 not_mapped BMKB151620-1 1p deletion loss of chromosome 1p NCIt:C36501 gene cancer DOID:162 NCIt:C36501 A cytogenetic abnormality that refers to the allelic loss of the chromosomal arm 1p. It has been described in gliomas, meningiomas, neuroblastomas, hepatocellular carcinomas, breast carcinomas, acinar prostate adenocarcinomas, pancreatic carcinomas, and adrenal gland adenomas. change_type:presence of;mod_type:sequence variation Presence of bmkb_II::1p:deletion sequence variation in gene loss of chromosome 1p/NCBI: 25